Cargando…

Comparative Study between Quantitative Digital Image Analysis and Fluorescence In Situ Hybridization of Breast Cancer Equivocal HER2 2+ Cases

Detalles Bibliográficos
Autores principales:	Ayad, E., Mansy, M., Elwi, D., Salem, M., Salama, M., Kayser, K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333907/ http://dx.doi.org/10.1155/2014/608254

Ejemplares similares

Comparative study between quantitative digital image analysis and fluorescence in situ hybridization of breast cancer equivocal human epidermal growth factor receptors 2 score 2(+) cases
por: Ayad, Essam, et al.
Publicado: (2015)

Indian Data on HER2 Fluorescence In Situ Hybridization in Invasive Breast Cancer with Immunohistochemically Equivocal Results As Per 2018 ASCO/CAP Guidelines
por: Nagarjun, B. R., et al.
Publicado: (2022)

Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results
por: Wang, Bo, et al.
Publicado: (2019)

Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis
por: Wang, Yuefeng, et al.
Publicado: (2017)

Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy
por: Crespo, James, et al.
Publicado: (2020)

Interphase fluorescence in situ hybridization analysis of fibroblast-like synoviocytes of patients with rheumatoid arthritis and osteoarthritis
por: Kiener, HP, et al.
Publicado: (2001)

Evaluation of Immunohistochemistry-Equivocal (2+) HER2 Gene Status in Invasive Breast Cancer by Silver DNA in Situ Hybridization (SISH) and its Association with Clinicopathological Variables
por: A. Musa, Zaidoon, et al.
Publicado: (2017)

Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization for Low and High Throughput HER2 Genetic Testing
por: Poulsen, Tim S., et al.
Publicado: (2013)

In-situ microscopy and 2D fluorescence spectroscopy as online methods for monitoring CHO cells during cultivation
por: Bonk, Sophia, et al.
Publicado: (2011)

Evaluation of hTERC (3q26) gain by fluorescence in situ hybridization (FISH) to predict the behavior of oral epithelial precursor lesions
por: Gabba, Silvia, et al.
Publicado: (2014)

Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
por: Agersborg, Sally, et al.
Publicado: (2018)

Fully Automated Fluorescent in situ Hybridization (FISH) Staining and Digital Analysis of HER2 in Breast Cancer: A Validation Study
por: van der Logt, Elise M. J., et al.
Publicado: (2015)

Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer
por: Gupta, Swati, et al.
Publicado: (2019)

Evaluation of ERBB2 mRNA Expression in HER2-Equivocal (2+) Immunohistochemistry Cases
por: Carretero-Barrio, Irene, et al.
Publicado: (2023)

Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer
por: Park, Kyeongmee, et al.
Publicado: (2011)

Serological Her2/neu-determination in patients receiving Herceptin(®)
por: Thomas, A, et al.
Publicado: (2001)

The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment
por: Marchiò, Caterina, et al.
Publicado: (2018)

Fluorescent in Situ Hybridization and Real-Time Quantitative Polymerase Chain Reaction to Evaluate HER-2/neu Status in Breast Cancer
por: Homaei Shandiz, Fatemeh, et al.
Publicado: (2017)

Digital Pathology: How Far Are We from Automated Tissue-Based Diagnosis?
por: Kayser, Klaus, et al.
Publicado: (2014)

Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus
por: Rygiel, Agnieszka M., et al.
Publicado: (2010)

Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines
por: Press, Michael F., et al.
Publicado: (2018)

Application of Fluorescence In Situ Hybridization Assisted by Fluorescence Microscope in Detection of Her2 Gene in Breast Cancer Patients
por: Lu, Fang, et al.
Publicado: (2022)

Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
por: Suydam, Camille, et al.
Publicado: (2023)

Anti-HER2 mAb plus calicheamicin immunoconjugate linked on liposomal vinorelbine induces ADCC and apoptosis in HER2-positive high grade DCIS
por: Giannos, J, et al.
Publicado: (2000)

Changes in the detection of human epidermal growth factor receptor 2 gene (Her-2) status for Her-2 fluorescent in situ hybridization testing
por: Xu, Ying, et al.
Publicado: (2022)

Structural basis for the oncogenic signalling complex formed by Grb2 and Gab2 in Her2 (ErbB2/Neu)-driven breast cancers and CML cells
por: Tsirka, T, et al.
Publicado: (2009)

Identification of HER2-positive breast carcinomas as a particular subset with peculiar clinical behaviours
por: Casalini, P, et al.
Publicado: (2001)

KRAS mutation in relation to HER2 overexpression/amplification in colorectal cancer
por: Bar, Julia K, et al.
Publicado: (2012)

Retracted: Application of Fluorescence In Situ Hybridization Assisted by Fluorescence Microscope in Detection of Her2 Gene in Breast Cancer Patients
por: Imaging, Contrast Media & Molecular
Publicado: (2023)

Characterizing Atypical BCL6 Signal Patterns Detected by Digital Fluorescence In Situ Hybridization (FISH) Analysis
por: Liew, Michael, et al.
Publicado: (2018)

Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis
por: Turashvili, Gulisa, et al.
Publicado: (2009)

HER-2 activation and TP53 inactivation as predictors of survival in breast cancer
por: Andersen, TI, et al.
Publicado: (2000)

Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer
por: Sui, Weiguo, et al.
Publicado: (2009)

Rescue of HER-2-positive breast carcinoma cells from dormancy by growth factors produced during wound healing
por: Agresti, R, et al.
Publicado: (2001)

Droplet digital polymerase chain reaction offers an improvisation over conventional immunohistochemistry and fluorescent in situ hybridization for ascertaining Her2 status of breast cancer
por: Suryavanshi, Moushumi, et al.
Publicado: (2019)

Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline
por: Kong, Hui, et al.
Publicado: (2022)

Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization
por: Yamashita-Kashima, Yoriko, et al.
Publicado: (2014)

Determination of the HER2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in Colombia
por: Plata, Adriana, et al.
Publicado: (2013)

Correlation of Immunohistochemistry and Fluorescence in Situ Hybridization for HER-2 Assessment in Breast Cancer Patients: Single Centre Experience
por: Bogdanovska-Todorovska, Magdalena, et al.
Publicado: (2018)

Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization
por: Annaratone, Laura, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5uugltq8e7h71jh4uoh8c64r47